Shire Announces Filing of Vyvanse for the Treatment of ADHD in Adults

Shire announced that it has submitted a supplemental new drug application to the FDA for Vyvanse for the treatment of attention deficit hyperactivity disorder (ADHD) in adults.

Vyvanse (lisdexamfetamine dimesylate) is a prodrug stimulant that is therapeutically inactive until metabolized in the body, at which point an active d-amphetamine is released, Shire said.

The company said it plans to announce full results from its Phase III clinical trial later this year.

The FDA approved Vyvanse Feb. 23 to treat symptoms of ADHD in children ages 6 to 12.